CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression

Figure 4

CD86 predicts progression of immune checkpoint blockades (ICBs) in LAML. (a)–(b) Correlations between CD86 and the pan-cancer T-cell inflamed score and the individual genes included in the T-cell inflamed signature. The T-cell inflamed score is positively correlated with the clinical response to cancer immunotherapy; (c) correlations between CD86 and molecular subtypes using seven different algorithms and AML signatures; (d) mutational profiles of neoadjuvant chemotherapy-related genes in low- and high-CD86 groups. (e) correlations between CD86 and the enrichment scores of several therapeutic signatures such as targeted therapy and radiotherapy.

(a)

(b)

(c)

(d)

(e)